InterCure Posts 2025 Revenue Growth, Positive Cash Flow as Recovery and Expansion Accelerate
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Intercure ( (IL:INCR) ).
InterCure reported its 2025 financial results on April 30, 2026, posting revenue of over NIS 270 million, up 13% year on year, and positive operating cash flow of NIS 17 million, alongside a narrowed net loss of NIS 37 million. Adjusted EBITDA nearly doubled to NIS 47 million, marking a twelfth consecutive half-year of positive Adjusted EBITDA, while the company repaid more than NIS 35 million in loans and ended 2025 with NIS 49 million in cash and shareholders’ equity of NIS 397 million.
Operationally, InterCure resumed production, imports and sales at its war-damaged Nir Oz facility in 2025, launched more than 75 new premium GMP products and secured NIS 82 million in war-related compensation advances from Israeli authorities. The company advanced its global expansion with first significant German revenues, agreed to acquire Botanico to bolster genetics and cultivation, invested in Cannasoul to deepen R&D and U.S.-focused capabilities, and saw insider share purchases that signal confidence as it continues to navigate market and legal complexities including Bazelet’s restructuring.
More about Intercure
InterCure Ltd., operating as Canndoc, is a leading, profitable and fast-growing medical cannabis company outside North America, with its main operations in Israel. Through its vertically integrated model, the company focuses on premium GMP-grade cannabis products, international expansion into markets such as Germany, and strategic research and cultivation partnerships.
Average Trading Volume: 62,225
Technical Sentiment Signal: Sell
Current Market Cap: ILs137.8M
Find detailed analytics on INCR stock on TipRanks’ Stock Analysis page.
